Fentanyl Transdermal Patch and Milnacipran: Interaction Details

Brand names
Milnacipran
Savella
Fentanyl Transdermal Patch
DuragesicAbstralSubsys +3 more
Same medicines, other forms
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page

A close look at the Fentanyl Transdermal Patch and Milnacipran interaction:

Share

Share this interaction

Fentanyl Transdermal Patch

Brand names
  • Duragesic
  • Abstral
  • Subsys
  • Ionsys
  • Actiq
  • Fentora

What Happens When You Take Fentanyl Transdermal Patch With Milnacipran

What can happen when they are taken together (rated Major)

Increased risk of

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

FentaNYL has proserotonergic activity, and serotonin syndrome has been reported when it is given together with drugs. of fentaNYL with -norepinephrine reuptake , , or other synthetic piperidine may likewise lead to serotonin syndrome.5

Patients should be monitored for signs of the syndrome, which include neuromuscular abnormalities, autonomic hyperactivity, and changes in mental status. The condition can be life-threatening.

Should it occur, the agents responsible must be stopped, and supportive care and any other needed therapy should be given.4 Symptoms typically begin within a few hours to a few days after the drugs are used together, though onset can be delayed beyond that window. When combined use is justified, the patient should be closely observed, especially when treatment is started and when doses are changed.321

The Fentanyl Transdermal Patch and Milnacipran Interaction, Explained

Milnacipran (Savella) is used for fibromyalgia, and the fentanyl patch (Duragesic) is a strong pain reliever. Both can raise , a brain chemical, so using them together can increase the risk of . This is a rare but serious reaction. The concern is mostly based on how the drugs work, not on many reported cases.

Warning signs include agitation or confusion, a fast heartbeat, sweating, diarrhea, shivering, tremor, or muscle stiffness or twitching. Symptoms often start within hours to a few days, especially after a start or a dose change. Please do not stop either medicine on your own. Talk with your pharmacist or doctor, who can watch you closely and manage this safely.

Mechanism: (PD). Milnacipran is an (inhibits and norepinephrine reuptake). Fentanyl is a proserotonergic synthetic piperidine . Neither is affected by a PK change here; the concern is . Risk of is increased.

  • Evidence: theoretical; labeling and case-report based. Severity: major. Onset: delayed (hours to days, may be later).
  • Monitor: neuromuscular findings (hyperreflexia, tremor, rigidity, clonus, shivering), autonomic hyperactivity (, mydriasis, diaphoresis, diarrhea), and mental status changes (agitation, delirium).
  • Management: if combination is warranted, observe carefully, especially at initiation and dose adjustment. If serotonin syndrome develops, discontinue the offending agents and give supportive care.

See the 9 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Fentanyl Transdermal Patch and Milnacipran Interact

The likely mechanism

In short: Fentanyl transdermal patch and milnacipran both raise serotonin activity, so taken together the effect can add up.
How Drug Interactions Work See this kind of interaction drawn out, step by step, in “When Effects Add Up or Cancel Out”, one chapter of our one-minute explainer. See how it works 

How to Manage the Fentanyl Transdermal Patch and Milnacipran Interaction

If your care team decides you need both medicines, they can manage this with careful observation, particularly when either one is started or the dose is changed.

  • Keep taking both exactly as prescribed unless your prescriber tells you otherwise.
  • Learn the warning signs: agitation or confusion, fast heartbeat, sweating, diarrhea, tremor, muscle stiffness or twitching, shivering.
  • Seek medical care right away if these appear, as can be life-threatening.
  • Tell your pharmacist or doctor about any new medicines or dose changes, including over-the-counter products and supplements.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Fentanyl Transdermal Patch or Milnacipran need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

5 reports from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Case scenario: opioid association with serotonin syndrome: implications to the practitioners

    A case report details associated in a 58-year-old man with a history of chronic back pain who had been stable on treatment for pain and depression. His regimen consisted of transdermal fentaNYL 75 mcg/hr patches, oxyCODONE 5 mg/acetaminophen 325 mg twice daily, celecoxib 200 mg twice daily, citalopram 40 mg once daily, and mirtazapine 50 mg at night.

    He also took doxazosin 4 mg daily and zolpidem 12.5 mg as needed for insomnia. Because he reported inadequate pain control, the fentaNYL schedule was changed so that the patch was replaced every 2 days instead of every 3 days.

    About 1 week after this fentaNYL increase, he reported anxiety, tremulousness, fever, and sweating. CloNIDine 0.2 mg every 4 hours was started without any improvement in symptoms.

    Symptoms persisted, and the next day he was given haloperidol and LORazepam for anxiety and agitation. He stopped his fentaNYL patch and, 2 days later, presented to the emergency room with opiate withdrawal.

    He was then diagnosed with serotonin syndrome even though the fentaNYL patch had been discontinued for 30 hours. Haloperidol, fentaNYL, oxyCODONE/acetaminophen, citalopram, and mirtazapine were stopped immediately, and symptoms resolved completely by the following day. Morphine sulfate was prescribed in place of fentaNYL, and citalopram and mirtazapine were restarted, with no recurrence of serotoninergic symptoms at follow-up.5

  2. Report 2 · Study title

    Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy

    linked to fentaNYL use during an esophagogastroduodenoscopy was reported in a 39-year-old woman who was also taking sertraline 100 mg daily as an outpatient. She first presented with hematemesis and a history of alcoholic cirrhosis.

    Before the esophagogastroduodenoscopy, an octreotide and pantoprazole drip was started, and she received 2 doses of fentaNYL 50 micrograms and 2 doses of midazolam 1 mg. After the procedure she became somnolent and extremely rigid in all four extremities, and vecuronium and etomidate were given for immediate intubation.

    The rigidity progressed, accompanied by diffuse diaphoresis, horizontal roving eye movements, and a fever of 105 degrees F. Because of the possibility of seizure activity, LORazepam 2 mg IV was given without improvement, and a propofol drip was started for continued during intubation.

    A CPK value of 2800 units/L and an ammonia level of 340 micromols/L pointed to . A CT scan of the brain ruled out an acute intracranial process, and the neurology team diagnosed serotonin syndrome secondary to an interaction between fentaNYL and sertraline.

    Propofol was continued for sedation, and supportive treatment consisted of a cooling blanket and cyproheptadine. After 3 days her temperature and CPK level had normalized, and she was later extubated without further complications.6

  3. Report 3 · Study title

    Serotonin syndrome precipitated by fentanyl during procedural sedation

    after IV fentaNYL administration during surgical procedures was reported in 2 patients who were also taking (sertraline and escitalopram). The first patient received IV fentaNYL (50 mcg), midazolam (2 mg), and 2 doses of propofol (60 mg and 40 mg) at an outpatient surgery center before a carpal tunnel release.

    After surgery she began shivering and became increasingly agitated, and she was transferred to the emergency department. On presentation she was combative, diaphoretic, and confused, could not follow commands, and was tachycardic and hypertensive, with hyperreflexia and ankle clonus.

    Creatinine kinase rose to 613 units/L on day 2 of hospitalization. The toxicology service treated her with escalating doses of without improvement.

    She was then intubated and sedated with a continuous propofol infusion. She was extubated after 2 days, all symptoms had resolved by day 3, and she was discharged home.

    The second patient, a 59-year-old woman, was admitted for an omentectomy and received IV fentaNYL 250 micrograms, etomidate, vecuronium, morphine, and cephazolin. After extubation she became hypoxic and acidotic and was reintubated and transferred to the ICU.

    On postoperative day 1 she was extubated, and she later became tachycardic and unable to follow commands. Examination showed agitation, diaphoresis, patellar hyperreflexia, and bilateral 3 to 4 beat ankle clonus.

    Laboratory evaluation showed a peak creatine kinase of 1161 units/L on postoperative day 2. She was treated with LORazepam and cyproheptadine, and symptoms resolved after 3 days.7

  4. Report 4 · Study title

    Serotonin toxicity caused by an interaction between fentanyl and paroxetine

    A case of postoperative after fentaNYL use for general anesthesia and postoperative analgesia was reported in a 60-year-old woman who was also receiving PARoxetine. Her outpatient medications were only PARoxetine and thyroxine, for depression and hypothyroidism.

    She was admitted for extensive resection of a recurrent left chest wall myxofibrosarcoma and received propofol and 200 mcg of fentaNYL for of anesthesia. She was given a further 800 mcg of fentaNYL intraoperatively (intermittent 50 mcg boluses), followed by a fentaNYL infusion (100 to 200 mcg/hr) for postoperative and analgesia (2545 mcg of fentaNYL received over 36 hours).

    The infusion was continued for 36 hours postoperatively, at which point neurological examination showed intermittent agitation, bilateral hypertonia and hyperreflexia, and bilateral inducible ankle clonus. Symptoms were more severe in the lower limbs and on the right side of the body.

    A CT scan of the brain was unremarkable, and all other findings, including a thyroid function test, were within normal limits except for elevated blood pressure (180/90 mmHg), which resolved spontaneously 24 hours after the procedure. fentaNYL was discontinued, and 24 hours later neurological symptoms had improved markedly, with complete recovery by postoperative day 4. She was ultimately discharged home without further complications.8

  5. Report 5 · Study title

    Serotonin syndrome caused by interaction between citalopram and fentanyl

    A 65-year-old woman treated with citalopram for depression developed after a fentaNYL patch was started. She had recently been diagnosed with myelodysplastic/myeloproliferative disease, and her regular medications included RABEprazole, tolterodine, HYDROcodone, and over-the-counter .

    She was hospitalized with abdominal pain and worsening back pain, and a spontaneous retroperitoneal was found. During hospitalization, her worsening back pain was treated with a fentaNYL transdermal patch (25 mcg/hr).

    Within 24 hours of starting fentaNYL, she progressively developed increasing confusion, agitation, combativeness, upper extremity tremors, myoclonic jerks, hyperreflexia, and unsteady gait, consistent with serotonin syndrome. (110 to 120 beats per minute) was also noted.

    A CT scan and laboratory values showed no abnormalities. fentaNYL was discontinued, and all symptoms resolved within 24 to 36 hours. Symptoms did not recur when oxyCODONE was started for the back pain. Based on the Naranjo adverse event probability scale, the association of this serotonin syndrome with of fentaNYL and citalopram was considered probable.9

Fentanyl Transdermal Patch and Milnacipran: Common Questions

How serious is the Fentanyl Transdermal Patch and Milnacipran interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

What symptoms should I watch for with Fentanyl Transdermal Patch and Milnacipran?

The interaction record lists as a possible effect of this combination. The signs it names include:

  • overactive reflexes
  • shaking (tremor)
  • stiff muscles
  • muscle twitching or jerking
  • peripheral hypertonicity
  • shivering
  • a fast heartbeat

Tell your prescriber or pharmacist if you notice any of these. Call 911 for severe symptoms such as fainting, chest pain or trouble breathing.

How is the Fentanyl Transdermal Patch and Milnacipran interaction managed?

If your care team decides you need both medicines, they can manage this with careful observation, particularly when either one is started or the dose is changed. Keep taking both exactly as prescribed unless your prescriber tells you otherwise. Learn the warning signs: agitation or confusion, fast heartbeat, sweating, diarrhea, tremor, muscle stiffness or twitching, shivering. Seek medical care ri… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "delayed". Effects tend to build up gradually over days to weeks.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Fentanyl Transdermal Patch and Milnacipran Interaction

Ask in your own words about taking Fentanyl Transdermal Patch and Milnacipran together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (9)

  1. Product Information: ACTIQ(R) oral transmucosal lozenge, fentanyl citrate oral transmucosal lozenge. Teva Pharmaceuticals USA, Inc. (per FDA), Parsippany, NJ, 2023. DailyMed
  2. Product Information: Fentanyl citrate intravenous, intramuscular injection, fentanyl citrate intravenous, intramuscular injection. Hospira Inc (per FDA), Lake Forest, IL, 2023. DailyMed
  3. Product Information: FENTORA(R) buccal tablets, fentanyl citrate buccal tablets. Teva Pharmaceuticals USA Inc (per FDA), Parsippany, NJ, 2023.
  4. Boyer EW & Shannon M: The serotonin syndrome. N Eng J Med 2005; 352(11):1112-1120. PubMed
  5. Rastogi R, Swarm RA, & Patel TA: Case scenario: opioid association with serotonin syndrome: implications to the practitioners. Anesthesiology 2011; 115(6):1291-1298. PubMed
  6. Alkhatib AA, Peterson KA, & Tuteja AK: Serotonin syndrome as a complication of fentanyl sedation during esophagogastroduodenoscopy. Dig Dis Sci 2010; 55(1):215-216. PubMed
  7. Kirschner R & Donovan JW: Serotonin syndrome precipitated by fentanyl during procedural sedation. J Emerg Med 2010; 38(4):477-480. PubMed
  8. Rang ST, Field J, & Irving C: Serotonin toxicity caused by an interaction between fentanyl and paroxetine. Can J Anaesth 2008; 55(8):521-525. PubMed
  9. Ailawadhi S, Sung KW, Carlson LA, et al: Serotonin syndrome caused by interaction between citalopram and fentanyl. J Clin Pharm Ther 2007; 32(2):199-202. PubMed
Was this write-up helpful?

Other Serious Interactions of Fentanyl Transdermal Patch and Milnacipran

Also serious with Milnacipran

Also serious with Fentanyl Transdermal Patch

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks. This interaction.
  • UnspecifiedThe timing of this interaction is not well characterized.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.